81675 München, de
+49 (89) 413138-29
WILEX completes Phase I program with anti-cancer drug WX-671 in healthy volunteers and conducts clinical Phase Ib study in cancer patients now
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.